Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
- PMID: 32800967
- DOI: 10.1016/j.hrthm.2020.08.009
Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Abstract
Background: Identifying patients with hypertrophic cardiomyopathy (HCM) who warrant a primary prevention implantable cardioverter-defibrillator (ICD) is crucial. ICDs are effective in terminating life-threatening arrhythmias; however, ICDs carry risks of complications.
Objective: The purpose of this study was to assess the incidence and predictors of appropriate ICD therapies, inappropriate shocks, and device-related complications in patients with HCM and primary prevention ICDs.
Methods: All patients with HCM who underwent primary prevention ICD implantation at Toronto General Hospital between September 2000 and December 2017 were identified. Therapies (shocks or antitachycardia pacing) for ventricular tachycardia >180 beats/min or ventricular fibrillation were considered appropriate.
Results: Three hundred two patients were followed for a mean 6.1 ± 4.3 years (1801 patient-years of follow-up). Thirty-eight patients (12.6%) received at least 1 appropriate ICD therapy (2.3%/y); the 5-year cumulative probability of receiving appropriate ICD therapy was 9.6%. None of the conventional risk factors nor the European Society of Cardiology risk score was associated with appropriate ICD therapy. In multivariable analysis, age < 40 years at implantation and atrial fibrillation were independent predictors of appropriate ICD therapy. In a subgroup of patients who had undergone cardiac magnetic resonance imaging before ICD implantation, severe late gadolinium enhancement was the strongest predictor of appropriate ICD therapies. ICD-related complications or inappropriate shocks occurred in 87 patients (28.8%), with an inappropriate shock rate of 2.1%/y; the 5-year cumulative probability was 10.7%.
Conclusion: The incidence of appropriate ICD therapies in patients with HCM and primary prevention ICDs is lower than previously reported; a high proportion of patients suffer from an ICD-related complication. Traditional risk factors have low predictive utility. Severe late gadolinium enhancement, atrial fibrillation, and young age are important predictors of ventricular tachyarrhythmias in HCM.
Keywords: Appropriate implantable cardioverter-defibrillator therapy; Hypertrophic cardiomyopathy; Primary prevention implantable cardioverter-defibrillator; Sudden cardiac death; Ventricular arrhythmia.
Copyright © 2020 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.Heart Rhythm. 2020 Jul;17(7):1107-1114. doi: 10.1016/j.hrthm.2020.02.008. Epub 2020 Feb 18. Heart Rhythm. 2020. PMID: 32084597 Free PMC article.
-
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.JAMA. 2007 Jul 25;298(4):405-12. doi: 10.1001/jama.298.4.405. JAMA. 2007. PMID: 17652294
-
Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.BMC Cardiovasc Disord. 2021 Feb 19;21(1):106. doi: 10.1186/s12872-021-01910-0. BMC Cardiovasc Disord. 2021. PMID: 33607967 Free PMC article.
-
Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator.Heart Rhythm. 2021 Jun;18(6):1012-1023. doi: 10.1016/j.hrthm.2021.01.019. Epub 2021 Jan 26. Heart Rhythm. 2021. PMID: 33508516 Review.
-
Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.Heart Rhythm. 2016 May;13(5):1155-1165. doi: 10.1016/j.hrthm.2015.12.048. Epub 2016 Jan 1. Heart Rhythm. 2016. PMID: 26749314 Review.
Cited by
-
Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings.Nat Genet. 2025 Mar;57(3):563-571. doi: 10.1038/s41588-025-02094-5. Epub 2025 Feb 18. Nat Genet. 2025. PMID: 39966645 Free PMC article.
-
Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy.Circ Arrhythm Electrophysiol. 2025 Feb;18(2):e013479. doi: 10.1161/CIRCEP.124.013479. Epub 2025 Feb 3. Circ Arrhythm Electrophysiol. 2025. PMID: 39895487 Free PMC article.
-
A pilot study for risk stratification of ventricular tachyarrhythmia in hypertrophic cardiomyopathy with routine echocardiography parameters.Sci Rep. 2024 Feb 15;14(1):3799. doi: 10.1038/s41598-024-54153-2. Sci Rep. 2024. PMID: 38360886 Free PMC article.
-
Assessment of dynamic cardiac repolarization and contractility in patients with hypertrophic cardiomyopathy.PLoS One. 2021 Feb 11;16(2):e0246768. doi: 10.1371/journal.pone.0246768. eCollection 2021. PLoS One. 2021. PMID: 33571287 Free PMC article.
-
Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects.Europace. 2023 May 19;25(5):euad091. doi: 10.1093/europace/euad091. Europace. 2023. PMID: 37102266 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical